dypiron, tramadol

PreclinicalSmall molecule

HHaEmek Medical Center, Israel

dypiron, tramadol is one of 4 small molecule programs targeting Peritonsillar Abscess. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peritonsillar AbscessActive, not recruiting

Peritonsillar AbscessPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Peritonsillar Abscess

#DrugCompanyPhaseTrials

Acanya

Pfizer

Preclinical

1 2

Flagyl

Ultram

dypiron, tramadol

HHaEmek Medical Center, Israel

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peritonsillar Abscess1 trial

The Effect of Adding Pain Relievers to Local Anesthesia Before Preforming Drainage in Peritonsillar Abscess

Unknown status·HHaEmek Medical Center, Israel·N/A·NCT01227200·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for dypiron, tramadol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dypiron, tramadol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dypiron, tramadol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HaEmek Medical Center, Israel company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHaEmek Medical Center, Israel

dypiron, tramadol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peritonsillar Abscess1 trial

References

Drug Info

Quick Facts

Related News